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n the context of evidence-based medicine,
1
randomized control-group trials (RCTs) are considered
to be the decisive level of scientifically proven evidence
as far as therapeutic aspects are concerned.
2 Placebo-
controlled trials, especially for certain psychiatric indi-
cations, are ranked higher in terms of evidence than
active control-group studies.
3 Especially in terms of
licensing perspectives, there is a demand from the
European Medicines Agency and the Food and Drug
Administration to demonstrate efficacy based on RCTs
including a placebo control group for obvious method-
ological reasons. The knowledge gained from noninter-
ventional (observational) studies (NIS) as well as from
single-case studies is only seen as being relevant when it
is an addition to such studies or a replacement in indi-
cations where empirical studies of a higher method-
ological degree are lacking. This view corresponds to the
general methodological understanding of empirical
research. Evidence graduation is geared to the fact that
for methodological reasons certain study designs yield
results that are more likely to be reliable. This corre-
sponds with the rules of the methodology of empirical
research.
4,5Thus, randomized control-group studies have
a higher value than nonrandomized or uncontrolled
studies.
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In recent years, so-called “effectiveness studies,” also
called “real-world studies” or “pragmatic trials,” have
gained increasing importance in the context of evidence-
based medicine. These studies follow less restrictive
methodological standards than phase III studies in terms
of patient selection, comedication, and other design
issues, and their results should therefore be better gener-
alizable than those of phase III trials. Effectiveness studies,
like other types of phase IV studies, can therefore con-
tribute to knowledge about medications and supply rele-
vant information in addition to that gained from phase III
trials. However, the less restrictive design and inherent
methodological problems of phase IV studies have to be
carefully considered. For example, the greater variance
caused by the different kinds of confounders as well as
problematic design issues, such as insensitive primary out-
come criteria, unblinded treatment conditions, inclusion
of chronic refractory patients, etc, can lead to wrong con-
clusions. Due to these methodological problems, effec-
tiveness studies are on a principally lower level of evi-
dence, adding only a complementary view to the results
of phase III trials without falsifying their results.      
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There is a general consensus that the results of phase III
studies are not fully generalizable: they have a high
internal validity but insufficient external validity. One of
the reasons for this is the strict selection of patients
according to various clinically relevant characteristics
such as the exclusion of suicidality, comorbidity, etc. For
this reason it has long been a tradition within clinical
psychopharmacology to complement the phase III trial
results with ones more strongly oriented towards every-
day clinical practice and conditions, ie, studies in patients
who better represent the “average” patients and treated
under conditions as close as possible to “routine” care,
eg, phase IV studies (Figure 1). However, it has thereby
always been stressed that because of many immanent
methodological problems, eg, biases due to lack of dou-
ble-blind conditions or any blinding, such as phase nat-
uralistic observational studies (NIS), only deliver com-
plementary knowledge and cannot falsify the results of
phase III studies.
6
However, this strict rule can be weakened if the phase
IV studies are performed, like phase III studies, as ran-
domized control-group studies in an unblinded or even
in blind or double-blind approach. 
Some experts seem inclined to attach a greater impor-
tance to the results of these studies than to the method-
ologically stricter phase III studies.
7 This might in par-
ticular be the result from criticism arising from the
increasingly common practice, especially in the USA, to
include, in phase III studies, not “real” patients from care
settings, but suitable persons found through advertise-
ments. Of course, rather than this questionable
approach, properly performed phase III studies in “real”
patients should be advocated. Even so, some experts
judge the “real-world approach” of effectiveness studies
to be more valuable than phase III trials, at least in terms
of clinical relevance.
Some methodological considerations on
effectiveness studies
Effectiveness studies are intended to fill the gap between
methodologically rigorous RCTs in the sense of phase
III trials and naturalistic observational studies. As such,
they are hybrids of the RCT methodology and natural-
istic designs and are therefore termed “practical clinical
trials.” 
8They are intentionally designed to evaluate the
effectiveness of the treatments under real-world condi-
tions and in patient samples representative of everyday
clinical practice (Table I). They can be performed as
RCTs, but less demanding designs are also possible. If
they use even a blind
9 or double-blind
10 RCT approach
they come close to phase III trials considering design
aspects, with the only difference being that patient selec-
tion is not that restrictive and that, eg, comorbidity or
comedication are allowed. 
In order to avoid guidelines completely losing their rela-
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Figure 1. The 4-phase model of clinical psychopharmacology. RCT, randomized controlled trial
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with too little generalizability, greater emphasis should
be placed on other empirical research approaches. A
drug that has been evaluated in placebo-controlled stud-
ies with the selection problems described above should
also be tested in studies with less restrictive methodol-
ogy, eg, randomized control-group studies versus a stan-
dard drug; the results should at least show a tendency
towards consistency. The 3-arm study design recom-
mended by the European regulatory authority,
EMEA/CPMP,
11 in which the experimental substance is
compared with placebo and a standard drug, delivers
more meaningful results but cannot avoid the problems
associated with the extensive selection of patients since
it still has a placebo group. Therefore, other types of
studies traditionally considered to be phase IV should
be part of the evaluation process.
It should be remembered that, traditionally, there was a
demand for a psychopharmaceutical drug to be clini-
cally evaluated in a phase model at various method-
ological levels of empirical research and with
approaches of different methodological stringency. This
means that evidence for efficacy and tolerability should
additionally be obtained from phase IV studies, which
are more closely oriented towards routine clinical
care,
12-17 to complement the results of phase III studies
with their strict methodology. In such a phase model of
clinical/pharmacological evaluation, the evidence from
each phase is seen to be complementary and part of the
overall evidence. This idea can no longer be found in the
systems currently used in guidelines to assess evidence,
since evidence is rated according to the study design
with the most demanding methodology for the respec-
tive therapy (eg, placebo-controlled studies) without
ascertaining whether consistent results are available
from less restrictive but more generalizable study types.
A future grading of evidence that is more relevant for
clinical reality should assess whether results are avail-
able from studies with both high internal (eg, control-
group studies) and high external (eg, effectiveness stud-
ies, observational studies) validity and whether the
results are principally congruent. So far, the current
interest in effectiveness studies is principally posi-
tive.
10,18,19 However, the results of these effectiveness
studies should not be overinterpreted due to their prin-
cipal methodological limitations (as demonstrated, eg,
for the Clinical Antipsychotic Trials of Intervention
Effectiveness [CATIE] trial).
6
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Clinical trials of “effectiveness”
More relaxed exclusion criteria, permitting wider range of:
Patients (eg, comorbidity not excluded)
Treatment settings and interventions (including adjunctive 
treatments)
Emphasis on clinical need to determine treatment doses, etc
Levels and/or types of psychopathology
Forms of outcome criteria, such as:
Time to discontinuation
Quality of life 
Preference of self-rating instruments or global ratings
Advantages
Higher external validity
Arguably greater applicability to “real-world” practice settings
Capacity to inform policy process
Longer duration can be easier achieved
Can enrol large number of patients more easily
Disadvantages
Internal validity limited
Cannot be used to examine effective dose ranges
Cannot make as meaningful clinical comparisons between
agents
Clinical trials of “efficacy”
Highly restricted inclusion criteria to reduce confounding biases
Randomization and blinding, also to reduce bias
Treatment driven exclusively by study protocol
Patients remain only in the treatment group originally assigned 
Fewer treatment adjustments are allowed
Strict limitations on adjunctive treatment
Measures taken to insure all members of treatment group 
receive same intervention(s)
Use of well-validated outcome assessment
Advantages
Higher internal validity for clinical effects
Higher internal validity for adverse effects, tolerability
Contextual and human factors controlled for
Considered “best quality” clinical evidence for informing 
treatment decisions
Disadvantages
Stringent inclusion criteria limit external validity
Outcome measures may not reflect crucial advantages and 
limitations of interventions being studied
Outcome measures may not address issues most important to
patients and families
Often short in duration
Table I. Some characteristics of clinical trials of “efficacy” vs trials of
“effectiveness.” 
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a phase III trial) such as comorbidity or comedication
increases the variance and results in a reduced signal-
to-noise ratio, which makes it more difficult to find dif-
ferences between two groups (β error problem), even if
these factors are adequately considered in the statistical
analysis. It might sometimes even be difficult to judge
without placebo conditions whether there is a real drug
effect, especially if the pre-post difference is unexpect-
edly low and if there are no differences between two
active comparators. Given the fact that these pragmatic
trials mostly compare two active compounds, it should
be accepted on the basis of the traditional methodology
of clinical psychopharmacological trials that only proof
of superiority in the statistical sense counts, while the
failure to demonstrate a statistically significant differ-
ence cannot be interpreted as showing that both treat-
ments are comparable.
3The latter conclusion is not per-
missible for principal methodological reasons. 
A different statistical design is required to demonstrate
equivalency: the so-called equivalency design. However,
this methodological approach is also far from the unam-
biguity of superiority trials. For example, without a
placebo control, which is characteristic for effectiveness
studies,
20-23 one cannot be sure that the active drugs are
being compared in a drug-sensitive sample (Table II).
3
The worst-case scenario is that the drugs show no out-
come difference because they are not effective at all in
the respective sample. This is not as unlikely as some
might believe. In the field of antidepressants, failed stud-
ies—in the sense that in a 3-arm study comparing an
experimental drug with a standard comparator and
placebo not even the standard comparator (internal val-
idator) differs from placebo—are quite common.
24 In
recent years there has even been an increasing number
of failed studies, especially in the United States, not only
in the field of antidepressants but also in the field of
antipsychotics, although the antipsychotics generally
have a larger effect size than antidepressants. Several
factors are relevant in this context, such as low inter-
rater reliability, especially in huge multicenter trials,
inclusion of less responsive patients, more chronic
patients with residual symptomatology or comorbid
patients, no restriction of permitted comedications, etc. 
In discussing methodological aspects of effectiveness
studies it should be questioned whether outcome crite-
ria such as “nondiscontinuation,” or similar categorical
end points like “level of caring,” preferably applied in
some effectiveness studies, really are ideal outcome cri-
teria, given the fact that they can easily be influenced by
the investigators (who may be biased by their expecta-
tions if they are not blinded) and are of poorer psycho-
metric value than dimensional ones. 
It can be generally questioned whether “nondiscontinu-
ation” really reflects only efficacy and tolerability
aspects, or whether other parameters beyond drug
effects are also involved, eg, confidence in the thera-
peutic concept. For example, therapeutic concepts like
psychotherapy, herbal drug therapy, etc, might be more
acceptable to a subgroup of patients, although they may
have a lower level of efficacy. Different aspects of toler-
ability can have different effects on discontinuation,
depending on the specific tolerability problems and on
the time patterns of side effects. Thus, one can presume
Clinical research
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Advantages Disadvantages
Placebo- Allow estimation of the assay sensitivity and thus  Perhaps higher risk from “nontreatment”
controlled internal validation of the study
studies Allow better evaluation of the clinical relevance Perhaps more limited generalisability of the results to the general
population
Smaller sample size
Lower study costs
Studies with Supply data on relative efficacy and tolerability Risk of false studies because assay sensitivity is lacking
an active At least theoretically no inactive treatment Equivalence/noninferiority not suitable as proof of efficacy
control Fewer dropouts due to lack of efficacy Active comparator may not be standard therapy
May be more acceptable to an ethics commission More dropouts due to adverse events
Tendancy to minimize efficacy differences
Larger sample sizes
Higher study costs
Table II. Advantages and disadvantages of using an active control or placebo in clinical studies.
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the start of a study result in an early dropout, the slow
development of weight gain rather a later dropout, and
tardive dyskinesia (TD) or in most cases even metabolic
disorder, a much later dropout. This means that a rough
measurement like “discontinuation” or “time to discon-
tinuation” causes a biased distortion per se with respect
to the individual antipsychotics being evaluated. This
becomes even worse if the transition from the pretreat-
ment antipsychotic to the study antipsychotic is taken
into consideration, in particular if it is direct, without a
sufficiently long washout phase. Depending on the phar-
macological profile of the respective pretreatment drug,
for example in terms of D2 potency, anticholinergic or
antihistaminergic properties, and the related pharmaco-
logical profile of the study drug, several problems can
appear immediately after transition.
25These can include
reduced antipsychotic efficacy, discontinuation symp-
toms, hangover of side effects wrongly attributed to the
study drug, pharmacodynamic interactions in terms of
oversedation, histaminergic, or cholinergic rebound phe-
nomena, etc. Thus, there are good and bad combinations
of drugs for this transition process. Theoretically, the best
transition is one in which the pretreatment and the study
drug are identical. There are also other critical issues that
need to be considered in this context.
26,27
Quality of life
Another preferred measure of global outcome used as a
primary outcome criterion in some effectiveness studies
is “quality of life.” There is no doubt that this is an
important outcome criterion which reflects the subjec-
tive dimension of the patient’s experience.
28-30 The clas-
sical approach in quality of life research assesses quality
of life using a self-rating scale in order to guarantee the
subjective perspective. The SF36
31,32 is particularly widely
used in psychiatry as well as in other fields of medicine,
but there are also several other scales to assess this
dimension.
33-35This leads to the general problem of self-
rating approaches for the assessment of the primary out-
come, if they are not complemented by an observer rat-
ing approach. For example, the Sequenced Treatment
Alternatives to Relieve Depression (STAR*D) study
18
widely relies on self-rating results to assess outcome in
terms of depression severity.
9
Generally, there are pros and cons for the use of self-rat-
ing scales. They give a complementary view to the observer
rating of the same construct/dimension.
36,37The correlation
between the observer ratings and self-ratings might not be
high and may be quite changeable, depending on the psy-
chopathological state in terms of severity and type of
symptoms.
38 It is often unclear exactly what self-ratings of
quality of life reflect; severity of the psychopathological
state in the global sense, certain dimensions of the psy-
chopathological state, eg, depression, current mood more
than real depressive symptoms, side effects of drugs, or the
psychosocial situation.
29,39-43 If such a scale is used as the pri-
mary outcome criterion of a study, it is doubtful whether
it is sensitive enough to detect intergroup differences in
treatment-induced changes, given the high variance of self-
rating in general and of self-ratings of quality of life in par-
ticular. For example, not many of the studies on antipsy-
chotics that used a quality of life scale as a secondary
outcome criterion found significant intergroup differ-
ences.
29,29 Thus, the use of a quality of life scale carries a
high risk of not finding significant differences between two
drugs, especially if both are active drugs.
Do effectiveness studies generally fulfil their claim of
treating less selective samples of patients than phase III
studies? At least some apparently do not. For example,
in the effectiveness study comparing olanzapine and
haloperidol in the treatment of schizophrenia,
44 of the
4386 patients assessed for eligibility, only 309 were
included in the study (7.0%). This rate is even somewhat
lower than the usual rate of 10% to 15% in phase III
studies.
45 Some effectiveness studies appear to have a dif-
ferent kind of selection of patients than phase III trials.
Often, patients with milder and more chronic symptoms
may be selected than is the case in phase III studies, thus
making it more difficult per se to demonstrate drug
effects and in particular differences between drug effects,
because a relevant subgroup of patients might be par-
tially unresponsive to a drug. The data from the Cost
Utility of the Latest Antipsychotics in Severe
Schizophrenia (CUtLASS) study serve as an example
here. In this study, the pre-post changes in the Positive
And Negative Symptom Scale (PANSS) positive score
after 52 weeks amounted to only 2.0 in the first-gener-
ation antipsychotic (FGA) arm and 1.5 in the second-
generation antipsychotic (SGA) arm; these changes are
extremely low, even when one takes into account that
this study was not an acute treatment study but rather a
switch study in partially improved/stabilized patients.
Also CATIE
46 and STAR*D
47 patients seem to be more
on the chronic and even partially refractory pole.
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problems of “effectiveness” studies in more detail, the
respective review by Möller on effectiveness studies in
the field of antipsychotics
6 should be taken into consid-
eration. It is interesting that some of these studies were
published in high-ranking journals, although some of
them have considerable methodological shortcomings
which mean that the conclusions drawn are not tenable,
especially not when they are used to falsify the results of
phase III studies. Most of these studies arrived at the
result that SGAs were generally not superior to FGAs
and are thus faced with the comment that not proving
superiority does not mean equivalence. The EUFEST
study was the only able to demonstrate superiority of
SGAs vs haloperidol. A finding of superiority is, for prin-
cipal methodological reasons (see above) more valid,
especially when considering the increased number of
confounders in effectiveness studies, than the finding of
no statistical differences, which is always difficult to
interpret. 
The CATIE study
The most famous of effectiveness studies on antipsy-
chotics is the CATIE study.
10 There is no doubt that the
CATIE study is an important study when one considers,
for example, the large sample size (N=1493 in 57 cen-
ters), the complex design with several parallel treatment
arms, the 18-month duration of treatment of the first
phase, inclusion of sequential treatment phases, etc
(phase 1 of the study was published in 2005
10). Also, the
double-blind conditions of this study and the sophisti-
cated and comprehensive statistical analysis of the
extensive database are appealing. The study has received
a lot of publicity, particularly in the general press, where
it was portrayed as showing that SGAs are for the most
part not better, but much more expensive, than FGAs.
This conclusion is not tenable because of the method-
ological failings described above and elsewhere.
6,48,49
However, to end on a more positive note, many other
results not only from phase 1 but also phase 2 and 3 are
of relevance for clinicians, eg, on different side-effect
patterns of individual SGAs, on metabolic issues, on
meaningful sequences of antipsychotic treatment in case
of partial nonresponse, on the unique efficacy of cloza-
pine in refractory patients, etc.
46,50
In the field of antidepressants there are not so many
effectiveness studies. To mention one there is the “Texas
Algorithm Study” which tried to demonstrate the supe-
riority of the algorithm approach in treating depressive
patients by comparing treatment outcome of depressive
patients from two different hospitals. The outcome was
more advantageous in the hospital where the algorithm
had been applied. However, the weakness of this study
was the baseline differences in the two samples, indicat-
ing that the patients in the algorithm sample probably
had a more positive prognosis. Two other studies which
evaluated the algorithm approach in a “real-world” RCT
could confirm the superiority of the treatment strat-
egy.
51,52
The most famous effectiveness study in the field of
depression treatment is the STAR*D study.
53 Even more
than the CATIE study, this study was a gigantic
endeavor in terms of sample size, complexity in design,
etc. It investigated under unblinded conditions two dif-
ferent sequential treatment approaches in depressive
outpatients, who were randomized at baseline to two dif-
ferent groups. At each level of the complex treatment
algorithm the outcome difference between the different
groups were evaluated. The methodological problems of
this study include the low Hamilton Depression Rating
Scale (HAMD) inclusion criteria (HAMD >14), the
recruitment of more or less chronic patients in poor psy-
chosocial conditions, overly optimistic power calcula-
tions with the consequence that latest for level 3 and 4
the study did not have the necessary power to detect
clinically relevant differences. None of the different drug
treatment approaches on each level of the sequential
treatment algorithm was statistically superior to any of
the others; at most some showed a numerical degree of
superiority. This “real-world” study reached no clear effi-
cacy results due to inherent methodological problems.
From a statistical point of view it does not seem unprob-
lematic that eg, the STAR*D study data were used to
generate about 100 publications answering different
questions, each of which reporting results based on mul-
tiple testings. Given all these problems it has to be ques-
tioned whether many really clinically relevant conclu-
sions can be drawn from this study. 
Of special methodological interest is the finding that the
outcome difference between an a posteriori defined effi-
cacy sample and an effectiveness sample was not as huge
as hypothesized.
54 This finding was supported by the
results of a naturalistic study on about 1000 depressive
inpatients where a similar approach of subdividing the
sample a posteriori had been applied.
55 These findings
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ple characteristics of phase III trials and “real-world” tri-
als,
56 the relevance for a different outcome does not have
to be as huge as anticipated. Thus, phase III studies are
apparently more than only “proof of concept” studies,
but have some, although limited, generalizability for
real-world patients.
Summary and conclusions
Effectiveness studies can contribute to our knowledge
about the use and effectiveness of medications. They
help to understand that even novel/expensive drugs have
their limitations and that it may not be possible to
demonstrate consistently their hypothesized superiority
in terms of efficacy, safety, compliance, quality of life, etc
under “real-world” conditions in chronic, partially refrac-
tory, or comorbid patients. In general they can also sup-
ply interesting data on dosing issues, sequences of drugs
in case of partial response and side-effect patterns.
Altogether, the effectiveness studies seem to have a lot
of methodological problems, making it difficult to
interpret their results. Given the fact that increased
variance due to the inclusion of chronic/poorly respon-
sive/comorbid patients, insensitive or problematic out-
come parameters, and inadequate sample size increase
the risk of a β-error (failure to detect a difference
although there is one), and that unblinded designs can
induce different kinds of biases. Caution has to be
applied when interpreting the results of trials with
such problems. 
In addition, it is questionable whether some effective-
ness studies really do represent the real-world treatment
situation better than classical acute and long-term phase
III studies, as some of them obviously also recruit a
selective patient sample, although the selection is of a
different kind than in phase III studies. Effectiveness
studies can therefore give only a complementary and not
a superior picture of reality. Effectiveness studies, espe-
cially those with an inadequate experimental design, are
definitely not suitable to cast doubt on the results of the
methodologically much stricter phase III studies. ❏
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Estudios de eficacia: ventajas y desventajas
En los últimos años los así llamados “estudios de efi-
cacia”, también denominados “estudios del mundo
real” o “ensayos pragmáticos” han ganado una
importancia creciente en el contexto de la medicina
basada en la evidencia. Estos estudios siguen están-
dares metodológicos menos restrictivos que los estu-
dios de fase III en términos de la selección de pacien-
tes, la comedicación y otros temas del diseño, y por lo
tanto sus resultados deben ser más generalizables
que los de los ensayos de fase III. Los estudios de efi-
cacia, como otros tipos de estudios de fase IV, pueden
por lo tanto contribuir al conocimiento de los medi-
camentos y aportar información relevante además de
la que se obtiene de los ensayos de fase III. Sin
embargo, el diseño menos restrictivo y los problemas
metodológicos inherentes a los estudios de fase IV tie-
nen que ser considerados cuidadosamente. Por ejem-
plo, la mayor varianza causada por los diferentes
tipos de confundentes así como los temas de diseños
problemáticos, tales como los criterios para los  resul-
tados primarios indiferentes, las condiciones de tra-
tamientos no ciegos, la inclusión de pacientes cróni-
cos refractarios, etc. pueden llevar a conclusiones
erróneas.    Debido a estos problemas metodológicos,
los estudios de eficacia se encuentran principalmente
en un nivel de evidencia más bajo, agregando sólo
una visión complementaria a los resultados de los
estudios de fase III sin desmentir sus resultados.
Avantages et inconvénients des études 
d’efficacité
Ces dernières années, les « études d’efficacité », aussi
appelées « études en conditions réelles » ou « essais
pragmatiques » ont acquis une importance croissante
dans le contexte de la médecine basée sur les preuves.
Ces études suivent des standards méthodologiques
moins restrictifs que les études de phase 3 en termes
de sélection des patients, de traitement concomitant
et d’autres problèmes de conception ; leurs résultats
peuvent donc être plus facilement généralisés que
ceux des études de phase 3. Les études d’efficacité,
comme d’autres types d’études de phase 4, peuvent
donc contribuer à la connaissance des traitements et
fournir une information pertinente, s’ajoutant à celle
des études de phase 3. Il faut cependant soigneuse-
ment prendre en compte leur schéma moins restric-
tif, et les problèmes méthodologiques inhérents aux
études de phase 4. Par exemple, une plus grande
variance due à différentes sortes de variables confon-
dantes et à des questions délicates de conception,
comme des critères de jugement primaires non sen-
sibles, des traitements qui n’ont pas été faits en
aveugle, une inclusion de patients chroniques réfrac-
taires etc… peuvent conduire à des conclusions erro-
nées. Les études d’efficacité, du fait  de ces problèmes
méthodologiques, sont d’un niveau de preuve nette-
ment plus bas, n’apportant qu’un regard complé-
mentaire sur les résultats des études de phase 3, sans
les falsifier. 
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